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Research onapolipoprotein E(APOE)hasconsistentlyrevealed arelationshipbetween thegene’sε4alleleandriskfordevelopment
of Alzheimer’s disease (AD). However, research with younger populations of ε4 carriers has suggested that the APOE ε4 allele may
in fact be beneﬁcial in earlier ages and may only confer risk of cognitive decline later in life. Accordingly, we and others have
proposed that APOE may represent an example of antagonistic pleiotropy. Antagonistic pleiotropy is an evolutionary biology
concept that proposes certain genes or alleles that may diﬀerentially impact ﬁtness during diﬀerent life stages. We critically review
this hypothesis in light of new research of the impact of APOE on cognition and neural integrity across the lifespan. We provide
recommendations for the revision of the antagonistic pleiotropy hypothesis of APOE and suggest important avenues for future
research in this area.
1.Introduction
Apolipoprotein E (APOE) is a protein coded by a gene
located on chromosome 19 and plays an important role
in cholesterol metabolism and synaptogenesis in the brain
[1, 2]. The APOE gene has three variants, or alleles: ε2,
ε3, and ε4. The ε4 allele has been consistently associated
with a higher risk of developing late-onset or sporadic
Alzheimer’s disease (AD)and a faster rate of disease progres-
sion (e.g., [3] ) ,a n da ss u c hi sp e r h a p st h em o s tf r e q u e n t l y
studied genetic risk factor for AD. Studies of nondemented
older adults utilizing event-related fMRI paradigms have
also suggested that ε4 carriers may more strongly recruit
task-related brain regions or may recruit additional brain
regions beyond task-related areas in order to compensate for
preclinical AD changes to achieve the same performance as
noncarriers (e.g., [4]). Preferentially recruited areas beyond
task-related regions have frequently been found to include
frontal regions with a possible predilection for the right
hemisphere [1].While ε4 carriers may initially maintain cog-
nitiveperformance through thesecompensatory recruitment
processes, once AD disease burden increases, compensatory
recruitment processes cannot sustain premorbid cognitive
performance levels and cognitive decline ensues [1].
Although APOE has been extensively studied in older
populations, its impact on cognition in younger ages has
been seldom considered. Interestingly, the few studies that
have investigated APOE’s impact in early life have frequently
reported that ε4 carriers may cognitively outperform non-
carriers. For instance, Yu et al. [5]f o u n dy o u n gε4 carriers to
have higher IQs than noncarriers, Alexander et al. [6]f o u n d
ε4ca rrier sa sy oun ga ss ixt oh a v eh igh erv erba lﬂ uen cys c or es
than noncarriers, and Wright et al. [7]f o u n dε4i n f a n t st o
producehigherscoresonthe24-monthMentalDevelopment
Index of the Bayley Scale.
As we proposed previously in our review on this topic
[1], these seemingly contradictory patterns of results may
be reconciled through the antagonistic pleiotropy concept.
Antagonistic pleiotropy is a concept from evolutionary
biology purporting that certain genes may impact ﬁtness
(i.e., survival and reproduction) diﬀerently during diﬀerent
life stages. Utilizing the concept of antagonistic pleiotropy,2 International Journal of Alzheimer’s Disease
we [1] suggested a model of the impact of APOE on
cognition across the lifespan. According to this model, we
have the following.
(a) Young ε4 carriers outperform noncarriers on tests of
memory and other cognitive domains.
(b) They may also recruit additional right hemisphere
frontal regions in order to achieve this advantage.
(c) By middle age, there are slight if any neurocognitive
diﬀerences between ε4 carriers and noncarriers.
(d) In more advanced ages, ε4 carriers may begin to
preferentially recruit right frontal brain regions in
ordertomaintain cognitive performance comparable
to noncarriers.
F i n a l l y ,t h em o d e lp r o p o s e st h a to n c eA Dd i s e a s eb u r d e n
suﬃciently accrues, ε4 carriers’ compensatory recruitment
will begin to fail, marking the beginning of cognitive
decline.
Muchresearch investigatingAPOEacrossthelifespanhas
been conducted since the antagonistic pleiotropy hypothesis
of APOE was proposed. We aim to review our model in light
of this most recent research. We provide recommendations
for revisions of this model to include recent ﬁndings
and suggest important areas for future research to evalu-
ate and expand the antagonistic pleiotropy hypothesis of
APOE.
We utilized the PubMed database in searching the lit-
erature for this review. All searches were limited to those
articles published in the last three years because of our
intent to focus on research published following our proposal
[1] of the antagonistic pleiotropy hypothesis of APOE in
2008. Search terms included “APOE and brain imaging,”
“APOE and cognition,” and “APOE and neuropsychology.”
The abstracts of articles returned through these searches
were examined and relevant articles were gathered. Articles
were considered relevant if they examined APOE genotype
in relation to cognitive performance or functional imaging
in any age group. The reference lists of obtained articles were
also searched by hand for additional relevant literature. The
articles discussed in this review as well as their sample size,
focus, and relevant ﬁndings are listed in Table 1.
2.APOEand CognitioninEarlyLife
Fortunately, research on the impact of APOE in early life has
become more prevalent in recent years. However, this work
has yielded inconsistent conclusions regarding the impact
of APOE on cognition early in the lifespan. Consistent
with the model of antagonistic pleiotropy, some studies
have reported an ε4 advantage in early life. Bloss et al.
[8] found that school-age children with the ε4 APOE allele
performed better than children with the ε2 allele on the
Rey Complex Figure Test (RCFT) copy trial. Children with
the ε2 allele were also more likely than carriers of other
alleles to be left-handed, a possible sign of abnormal neural
development. Because of ε4 carriers’ apparent beneﬁts and
ε2 carriers’ deﬁcits in this young sample, a reversal of
typical ﬁndings in older age groups, the authors suggested
that these results are consistent with antagonistic pleiotropy.
Also in support, Mondadori [46] reported young adult ε4
carriers to outperform noncarriers on the delayed recall
portion of an episodic memory task, although no other
diﬀerences by genotype were found in working memory,
visuospatial processing, or executive functioning. Marchant
et al. [9] reported that 18 to 30-year-old APOE ε4 carriers
showed an advantage over noncarriers on tests of frontal
lobe functioning. No´ ee ta l .[ 10] studied a sample with
moderate to severe traumatic brain injury (TBI) and found
that while ε4 carriers were more severe at baseline, they also
exhibited a steeper rate of improvement in working memory
compared to noncarriers. This work is consistent with our
model [1], suggesting an advantage in cognition and head
injury outcome for young ε4 carriers.
Nevertheless, studies reporting the opposite ﬁndings are
equally as prevalent. Gozal et al. [47] found that the APOE
ε4 allele was associated with cognitive impairment in 5-
to 7-year-old children with obstructive sleep apnea. Dennis
et al. [11]a n dF i l b e ye ta l .[ 12] both failed to ﬁnd cognitive
diﬀerences between ε4 carriers and noncarriers in their 20’s
and 30’sand Liu et al. [48]f a i l e dt oﬁ n dd i ﬀerencesby APOE
genotype in those younger than age 50. Hiekkanen et al.
[13] also reported that APOE genotype was unassociated
with one-year outcome of mild TBI in adults aged 18 to
70. Luciano et al. [14], studying a sample of 70-year olds
in the Lothian Birth Cohort, failed to ﬁnd diﬀerences by
APOE genotype in IQ measured at age 11. It is noteworthy
that several studies ﬁnding reduced cognition in ε4 carriers
only did so when carriers also had other risk factors for AD.
For instance, Ruiz et al. [15]r e p o r t e dﬁ n d i n gn od i ﬀerences
in cognition by APOE status in a sample of adolescents.
However, the authors discovered that ε4 carriers who also
carriedtheMTHFR677TTallele,agenepossiblydetrimental
to cognition, displayed signiﬁcantly worse cognitive per-
formance than adolescents with other allelic combinations.
Bloss et al. [16] found that school-age children with the
APOE ε4 allele as well as a family history of AD performed
more poorly on standardized achievement tests of reading
and language and the RCFT copy. Importantly, there was no
main eﬀect of APOE genotype; children with the ε4a l l e l e
were only found to exhibit depressed scores when they also
had a family history of AD, suggesting that these two risk
factors interact to inﬂuence cognition. Acevedo et al. [17]
found that 7 to 10-year-old ε4 carriers were more likely
to have been placed in an intensive care unit after birth,
achieved lower spatial memory retention, and, among girls
only, ε4 carriers achieved lower visual recall scores on the
Family Pictures Test. The authors conceptualized the latter
ﬁndingasrepresentinganinteractionbetweenthepotentially
genderedriskofAD,which ismoreprevalentinwomen,with
the APOE ε4 risk factor. It is important to note that while the
authors indicated that participants’ birth complicationswere
unlikely to have impacted cognition, the presence of birth
complications was not controlled for in analyses. Because ε4
carriers were more likely to experience birth complications,
this fact could explain the association between ε4 status and
cognition in this sample.International Journal of Alzheimer’s Disease 3
Table 1: Samples, methods, and relevant ﬁndings of reviewed articles.
Article Sample Methods used Relevant ﬁndings
Bloss et al.
[8] 147 youth, age 11–16 Assessment of verbal cognition and
visuospatial processing
APOE ε4 carriers performed better than ε2 carriers
on a test of visuospatialprocessing
Marchant
et al. [9]
156 college students,
age 18–30
Assessment of spatial working memory,
estimated IQ, immediate verbal memory,
verbal ﬂuency, sustained attention, and
decision-making ability
APOE ε4 carriers showed an advantage over
noncarriers on tests of verbal ﬂuency and
decision-making
No´ ee ta l .
[10]
82 patients currently
with post-traumatic
amnesia (PTA; mean
age = 31.5) and 107
patients without PTA
(mean age = 29.5)
Assessment of PTA severity, verbal memory,
and working memory
APOE ε4 carriers were more severe at baseline but
exhibited a steeper rate of improvement in working
memory over time than noncarriers
Dennis et al.
[11]
24 young adults
(mean age = 21.3)
Functional MRI during the encoding
portion of an object memory task followed
by a recall session24 hours later, and an
assessmentof memory, processing speed,
attention, and executive functioning
APOE ε4 carriers and noncarriers performed
similarly on all cognitivetests, while ε4 carriers
showed more bilateral MTL activity and functional
connectivity of MTL and posterior cingulate and
perilimbic structures during memory encoding
Filbey et al.
[12]
36 healthy adults, age
50–75 and 16 adults,
age 19–32
Functional MRI during a visual working
memory task and an assessmentof global
cognition
APOE ε4 carriers and noncarriers did not diﬀer in
cognitive performance, while ε4 carriers showed
more medial frontal and MTL activity compared to
noncarriers during the working memory task.
Older ε4 carriers also showed decreased activation
compared to noncarriers in several frontal, parietal,
temporal, and cingulate cortices
Hiekkanen
et al. [13]
33 mild TBI patients
(mean age = 44.2)
Structural MRI, assessmentof PTA, and
Glasgow Coma Scale ratings over a one year
follow-up period
While MRI ﬁndings and PTA severity predicted
TBI outcome after one year, APOE genotype was
unassociated with TBI outcome
Luciano et al.
[14]
1,091 participants in
the Lothian Birth
Cohort
Assessment of IQ at age 11 and measures of
global cognition, working memory,
nonverbal reasoning, construction, verbal
ﬂuency, and processing speed at age 70
APOE genotype was unrelated to IQ at age 11, yet
the ε4 allele was associated with lower processing
speed, nonverbal reasoning, and general cognition
measured at age 70
Ruiz et al.
[15]
412 participants, age
13–18
Assessment of verbal and quantitative skills
and problem solving ability
APOE genotype was not associated with cognition,
but ε4 carriers who also had the MTHFR 677TT
allele had lower quantitative and reasoning abilities
Bloss et al.
[16] 109 youth, age 11–16 Assessment of verbal cognition and
visuospatial processing
APOE genotype was not associated with cognition,
but ε4 carriers who also had a family history of AD
had lower verbal and visuospatial abilities
Acevedo
et al. [17] 50 youth, age 7–10
Assessment of general intelligence, memory,
attention, executive functioning, and
visuospatial processing
APOE ε4 carriers were more likely to have been
placed in intensive care after birth and had lower
spatial memory abilities, especially among girls
Filippini
et al. [18] 36 adults, age 20–35
Structural MRI, perfusion MRI at rest, and
functional MRI at rest and during a
memory encoding task
APOE ε4 carriers showed more connectivity among
default-mode network regions and more
hippocampal activation during the memory task
than noncarriers
Kukolja
et al. [4]
18 healthy older
adults (mean age =
60.5)
Functional MRI during a spatial contextual
memory task
APOE ε4 carriers had poorer memory performance
than noncarriers. ε4 carriers also more strongly
activated prefrontal, temporal, and parietal regions
during encoding than did noncarriers but showed
less activation in prefrontal cortex during retrieval
Trivedi
et al. [19]
155 healthy adults,
age 18–84
Functional MRI during episodic encoding
and metacognitive self-appraisal tasks
APOE ε4 carriers showed increasing hippocampal
activation with age during the memory task, while
noncarriers showed age-related reductions in
hippocampal activity
Wierenga
et al. [20]
22 healthy older
adults (mean age =
78.10)
Functional MRI during an object naming
task
APOE genotype was unrelated to naming ability,
yet ε4 carriers exhibited greater activity in the left
fusiform, right perisylvian cortex, and bilateral
medial prefrontal cortex than noncarriers4 International Journal of Alzheimer’s Disease
Table 1: Continued.
Article Sample Methods used Relevant ﬁndings
Seidenberg
et al. [21]
69 healthy older
adults, age 65–85
Functional MRI during a semantic memory
task
Those with an ε4 allele and family history of AD
showed greater activations in bilateral cingulate,
temporoparietal, and prefrontal regions than those
without risk factors. ε4 carriers also showed greater
recruitment of right middle frontal regions
Woodard
et al. [22]
57 older adults, age
65–85 with or
without amnestic
MCI
Functional MRI during a semantic memory
task
Those with an ε4 allele and family history of AD
displayed increased activation in temporoparietal,
hippocampal, and posterior cingulate regions than
those without risk factors. MCI patients showed
similar patterns along with enhanced frontal
recruitment
Bartr´ es-Faz
et al. [23]
32 older adults with
mild memory
impairments (mean
age = 66.83)
Functional MRI during a face-name
learning task
APOE ε4 carriers showed increased connectivity of
the hippocampus with anterior cingulate,
postcentral gyrus, and caudate nucleus during
encoding compared to noncarriers
Borghesani
et al. [24]
14 healthy older
adults
Functional MRI during a visuospatial
memory task
APOE ε4 carriers showed less MTL activation
during encoding than noncarriers despite equal
performance
Xu et al. [25] 74 healthy adults, age
50–65
Functional MRI during an episodic face
recognition task
APOE ε4 carriers showed reduced activation in
posterior and anterior cingulate and precuneus
than noncarriers during recall
Suthana
et al. [26]
32 healthy older
adults (mean age =
61.1)
Functional MRI during a word memory task APOE ε4 carriers displayed reduced hippocampal
activation during encoding than noncarriers
Welsh-
Bohmer et al.
[27]
507 healthy older
adults, age 66–103
Assessmentof object naming,verbal ﬂuency,
memory, construction, processing speed,
and global cognition
APOE genotype was unrelated to all measures of
cognition
Adamson
et al. [28]
50 healthy pilots, age
50–76 Structural MRI and assessmentof memory
APOE ε4 carriers performed more poorly on visual
paired associate recall than noncarriers but showed
no structural brain diﬀerences
Debette et al.
[29]
717 healthy adult
oﬀspring from the
Framingham cohort
(mean age = 59)
Structural MRI, assessmentof memory,
abstract reasoning, and mental ﬂexibility,
and determination of parental dementia
APOE ε4 carriers were more likely to have a parent
with dementia. Among ε4 carriers, parental
dementia was associated with lower memory
performance
Honea et al.
[30]
53 healthy older
adults age, 60 and
older
Structural MRI, diﬀusion tensor imaging,
and an assessmentof memory, language,
executive functioning, and visuospatial
ability
APOE ε4 carriers performed more poorly on
measures of memory and working memory and
had smaller hippocampi and parahippocampal FA
Caselli et al.
[31]
815 healthy adults
age, 21–97
A longitudinal assessmentof long-term
memory, global cognition, verbal ﬂuency,
and visuospatial abilities
APOE ε4 carriers were found to experience
memory decline in their 50’s, while noncarriers did
not show decline until their 70’s. A dose-dependent
eﬀect was found in which ε4 homozygotes
displayed earlier memory decline than
heterozygotes. ε4 carriers showed steeper decline
than noncarriers in memory, global cognition, and
visuospatial processing
De Blasi
et al. [32]
620 healthy older
adults, age 65–85 Assessment of memory and global cognition
While APOE ε4 was associated with memory
encoding and recall, it was unrelated to global
cognition
Knopman
et al. [33]
1130 adults (mean
age = 59)
Assessment of memory, verbal ﬂuency,
processing speed, and vascular risk factors
APOE ε4 carriers exhibited increased decline in
processing speed and memory compared to
noncarriers
Mungas
et al. [34]
369 older adults
(mean age = 74.3)
Assessmentof object naming,verbal ﬂuency,
memory, and working memory
APOE ε4 carriers exhibited lower episodic memory
scores at baseline and increased decline in memory
and executive functioning than noncarriers
Walhovd
et al. [35]
161 older adults, age
55–90
Structural MRI, FDG-PET, and an
assessmentof memory
APOE ε4 allele was associated with poorer
recognition memory beyond imaging variablesInternational Journal of Alzheimer’s Disease 5
Table 1: Continued.
Article Sample Methods used Relevant ﬁndings
Hayden et al.
[36]
2957 older adults
(mean age = 74)
Longitudinalassessmentof global cognition
and family history of dementia
APOE ε4 carriers had lower baseline global
cognitionand steeper decline in cognition than
noncarriers
Whitehair
et al. [37]
516 amnestic MCI
patients, age 55–90
Longitudinalassessmentofglobal cognition,
memory, processing speed, verbal ﬂuency,
working memory, naming, and functioning
APOE ε4 carriers had lower baseline scores on
nearly every assessmentand also showed steeper
declines in nearly every domain
Yaﬀee ta l .
[38]
2509 healthy older
adults, age 70–79
Longitudinalassessmentof global cognition
and health variables
APOE ε4 allele was associated with likelihood of
cognitive decline
Thambisetty
et al. [39]
94 healthy older
adults (mean age =
69.2)
Longitudinal structural MRI, PET imaging,
and assessmentof memory, verbal
intelligence, verbal ﬂuency, attention,
working memory, and executive functioning
APOE ε4 carriers performed more poorly on
category ﬂuency and also had greater decline in
regional cerebral blood ﬂow, particularly in areas
commonlyimplicated in AD
Raz et al. [40] 189 healthy adults,
age 18–82
Assessment of ﬂuid intelligence, memory,
executive functioning, and processing speed
APOE ε4 carriers evidenced greater age-related
interference eﬀects in a Stroop task than
noncarriers
Barabash
et al. [41]
89 amnestic MCI
patients (mean age =
79) and 90 healthy
adults (mean age =
76)
Longitudinalassessmentof cognitive
diagnosis
APOE ε4 allele was associated with higher risk of
developing MCI, but not AD
Wang et al.
[42]
20 healthy older
adults (mean age =
75) and 58 amnestic
MCI patients (mean
age = 76.6)
Longitudinalstructural MRI and an
assessmentof global cognition, memory,
attention, language, construction, and
abstract thinking
APOE ε4 allele was unassociated with rate of
decline in cognition or brain volumes
Heun et al.
[43]
200 healthy older
adults (mean age =
80.3)
Longitudinalassessmentof cognitive
diagnosis,global cognition, memory,
construction, attention, and language
APOE ε4 allele was unassociated with likelihood of
conversion to MCI
Carri´ on-
Baralt et al.
[44]
87 nonagenarians
Assessment of global cognition, memory,
naming, verbal ﬂuency, attention, and
processing speed
APOE ε4 carriers displayed higher global cognition,
attention, visuospatial processing, naming,praxis,
and memory encoding than noncarriers
Kozauer
et al. [45]
659 adults (mean age
= 58.4)
Longitudinalassessmentof global cognition
and memory
APOE ε4 carriers in the younger cohort, who were
in their 50’s, showed increased decline in memory
and global cognition compared to noncarriers.
However, older ε4c a r r i e r si nt h e i r7 0 ’ ss h o w e dn o
cognitive diﬀerences from noncarriers
While these studies do not unequivocally support our
model of antagonistic pleiotropy and APOE [1], interpreta-
tion of the ﬁndings of studies in this area is complicated by
thenature ofthesamples studied. When thepotential beneﬁt
of holding an ε4 allele could be conﬁned to a very narrow
w i n d o we a r l yo ni nt h el i f e s p a n ,t h ei m p o r t a n c eo fs t u d y i n g
the impact of APOE in speciﬁc age ranges and of examining
the interaction of age and APOE status in lifespan samples
becomes apparent. Moreover, it is likely that APOE status
interacts with other genetic and environmental risk factors
(e.g., birth complications, MTHFR 677TT allele, family
history of AD) to impact cognition [15–17], implying that
participants’ additional risk factors beyond APOE should
also be considered. Taking such measures will greatly clarify
the literature in this area and lead to more reliable ﬁndings
regarding the impact of APOE on cognition in early life.
3.APOE andCompensatoryRecruitmentin
EarlyLife
Although comparatively less research has examined neural
activity than cognition early in the lifespan, fMRI research
with children has produced results more consistently sup-
porting our model of antagonistic pleiotropy and APOE.
Dennis et al. [11] examined activity in medial temporal
lobe(MTL)structuresimportantformemoryandfunctional
connectivity between MTL regions and other brain regions
using event-related fMRI. Young adult participants were
asked to encode visually presented stimuli and were given a
surprise recall session 24 hours later. Results revealed that ε4
carriers had more bilateral activity in MTL structures during
memory encoding and had more functional connectivity
of MTL structures with posterior cingulate and perilimbic6 International Journal of Alzheimer’s Disease
regions than noncarriers. However, ε4 carriers also showed
a tendency towards decreased connectivity between anterior
and posterior cortices. Dennis et al. [11] suggested that
ﬁndings of increased functional connectivity between MTL
regions and other regions known to be aﬀected by AD
(e.g., posterior cingulate) may suggest that APOE begins
to be expressed in AD-associated brain regions long before
cognitive decline and that these ﬁndings may also be
consistent with antagonistic pleiotropy. Filbey et al. [12,
49] also found that young adult ε4 carriers showed more
medial frontal [12, 49], cingulate [49], and MTL [12]
activity compared to noncarriers in a working memory task.
In a slightly older sample of 20-to-35-year-olds, Filippini
et al. [18]r e p o r t e dε4 carriers to have more default
mode network (DMN) connectivity and more hippocampal
activation during a memory encoding task than noncarriers.
However, at least one study [46] reported that young adult
ε4 carriers exhibited less neural activity in bilateral MTL
and left frontal regions during the encoding and retrieval
portions of an episodic memory task than performance-
matched noncarriers. The authors attributed these ﬁndings
to enhanced neural eﬃciency of memory networks in young
adult ε4 carriers [46].
The majority of these studies appear to support the
proposed model of antagonistic pleiotropy in that ε4 carriers
tend to recruit task-related regions more intensely than
do noncarriers. However, the above studies provide less
support for the proposal that ε4 carriers will preferentially
recruit more right hemisphere frontal regions during task
performance. While it is unclear whether the ε4 carriers
studied by Dennis et al. [11] also showed higher activations
in frontal regions because the authors focused on activity
in MTL structures, Filippini et al. [18] used voxel-based
morphometry and did not reveal any involvement of frontal
regions by APOE status. Additionally, while Filbey et al. [12]
indicated that ε4 carriers recruited medial frontal regions
more than noncarriers, this may be due to the nature of the
task, as working memory tasks are more frontally-mediated
than assessments of episodic or semantic memory.
4.APOEand CompensatoryRecruitmentin
Old Age
As Trachtenberg et al. [50] note in their thorough review,
research examining the blood-oxygen-level-dependent
(BOLD) response using fMRI has produced inconsistent
ﬁndings regarding the impact of APOE that are not easily
understood even when considering diﬀerences in task,
family history of AD, and age. While this observation
was also borne out in our review of recent research with
older adults, the majority of studies provided evidence of
compensatory neural recruitment in older APOE ε4 carriers.
Of studies that found evidence of compensatory recruit-
ment in nondemented older adults with the ε4 allele, many
f o u n da ni n c r e a s ei na c t i v a t i o no ft a s k - r e l a t e dr e g i o n s ,
regions known to be aﬀected by AD (e.g., posterior
cingulate), and frontal regions. For instance, Bookheimer
et al. [51] found that nondemented middle-aged and older
adult ε4 carriers more strongly activated AD-associated
brain regions, such as hippocampal, parietal, and prefrontal
regions, than ε3 carriers during a paired-associate word
learning task. Furthermore, the authors found that the
magnitude and extent of neural activation at baseline was
predictive of cognitive decline after two years, as would
be expected according to the compensatory recruitment
hypothesis [51]. Dickerson et al. [52] also reported ﬁndings
suggestive of compensatory recruitment in a sample of
cognitively intact older adults and patients with MCI or
AD. Results revealed that APOE ε4 carriers, regardless of
diagnosis, showed enhanced hippocampal activity during
encoding in a face-name memory task [52]. Similarly,
Bondi et al. [53] reported healthy older adult ε4 carriers
display more intense and widespread activations in parietal,
frontal, and right MTL regions than noncarriers during
encoding in a picture learning task. Notably, ε4 carriers
exhibited reduced activations in left hippocampal regions
compared to ε3 carriers, supportive of our model’s [1]
prediction of a predilection for compensatory responses in
the right hemisphere [53]. A more recent study by Kukolja
et al. [4] found that nondemented older ε4 carriers more
strongly activated right hippocampal and predominantly
right prefrontal, temporal, and parietal regions during
the encoding portion of a spatial context memory task
than did noncarriers, as would be expected according to
antagonistic pleiotropy. However, the authors also reported
that ε4 carriers showed less activity in the prefrontal cortex
bilaterally during retrieval. Interestingly, the authors noted
thathippocampal activity was inverselyassociated withitems
remembered for ε4 carriers but positively associated with
recall for noncarriers. The opposite relationship was found
in bilateral inferior frontal gyrus, right middle frontal gyrus,
and left parietal cortex, the activity of which was positively
associated with recall among ε4 carriers. In light of these
ﬁndings, Kukolja et al. [4] suggested that compensation
may occur during encoding among ε4 carriers, coinciding
with increased frontal activations during this portion of
the task. However, they note that activity decreases during
the retrieval portion of the task reveal the likelihood of
approaching cognitive decline. Filbey et al. [12] also found
nondemented olderadultε4 carriersto more strongly recruit
medial frontal and temporal regions during a working
memory task, although ε4 carriers showed less activity than
noncarriers in several other frontal and temporal regions.
Trivedi et al. [19]e x a m i n e dal a r g es a m p l ef r o ma g e1 8t o8 4
using an episodic encoding task and found that ε4 carriers
exhibited increases in hippocampal activity with age, while
noncarriers showed age-related decreases in hippocampal
activity. Wierenga et al. [20], studying cognitively intact
older ε4 carriers with a confrontation naming task, found
that ε4 carriers displayed increased activations compared
to noncarriers in the left fusiform gyrus, bilateral medial
prefrontal cortex, and right perisylvian cortex despite equal
performance acrossthegroups.Seidenbergetal.[21]utiliz ed
a semantic memory task designed to require low levels
of eﬀort and produce high accuracy rates in a cognitively
normal sample of older adults. They found that those with
the ε4 allele and a family history of AD preferentially
recruited bilateral posterior cingulate/precuneus, bilateralInternational Journal of Alzheimer’s Disease 7
temporoparietal junction, and bilateral prefrontal cortex
than participants without any AD risk factors during recall
offamiliar versusunfamiliar names. Moreover, in comparing
participants with both the ε4 allele and family history of AD
to those with just a family history, ε4 carriers exhibited more
activation in right middle frontal and right supramarginal
gyri. Seidenberg et al.’s [21] results suggest that the APOE ε4
allele was uniquely associated with preferential activation of
right hemisphere frontal regions, as we have suggested [1].
Woodard et al. [22] also used a low-eﬀort famous name
discrimination task and found that participants with an
ε4 allele and family history of AD displayed increased
activation compared to those without risk factors in lateral
temporoparietal regions, left hippocampus, and posterior
cingulate/precuneus. Participants with MCI also showed
similar increases in activations, but they did not show
enhanced recruitment of the hippocampus and instead
showed increased activations in frontal regions, suggesting
that compensatory recruitment processes may evolve with
changes in cognition and neuropathology burden [22].
Finally, Bartr´ es-Faz et al. [23] studied hippocampal connec-
tivity in older adults with mild memory impairments. They
reported that ε4 carriers exhibited increased connectivity
of the hippocampus with the anterior cingulate, inferior
parietal/postcentral gyrus, and the caudate nucleus during
the encoding portion of a face-name memory task. The
authors suggested that this may indicate increased cortical-
subcortical connections in the episodic memory networks in
ε4 carriers.
Overall, these studies uniformly support the presence of
compensatory neural recruitment processes in ε4 carriers.
Yet, while some studies support our proposal [1]t h a tε4
carriers would have a predilection for recruiting right hemi-
sphere regions [4, 20, 21], this was not true for all studies
reviewed [12, 19, 22, 23]. This could be a factor of type
of task, as Kukolja et al. [4], who found the most evidence
for a right hemisphere dominant compensatory response,
used a spatial context memory task, which may be expected
to preferentially activate right hemisphere regions due to
the involvement of visuospatial processing. In contrast,
several studies that found a predominantly left hemisphere
or bilateral compensatory response (e.g., [12, 20–22]) used
tasks (e.g., confrontation naming, working memory, and
famous name discrimination) that may be more expected to
activate left rather than right hemisphere regions due to the
emphasis on language.
There were also studies reviewed which did not support
the existence of a compensatory recruitment process in older
cognitively intact ε4 carriers. Johnson et al. [54]f o u n d
that APOE genotype alone did not impact neural activity
during a self-appraisal task in middle-age adults, although
APOE status did interact with a family history of AD to
produce greater frontal and posterior cingulate activations
in ε4 carriers without a family history of AD. Johnson
et al. [55] reported similar results in an earlier study of
middle-age adults using an episodic memory task. While
APOE ε4 carriers with no family history of AD did show
the predicted enhanced recruitment of MTL structures, ε4
carriers with a family history of AD actually showed the
lowest levels of MTL recruitment of all participant groups
[55]. As noted by the authors, [54, 55], such results suggest
that the impact of APOEon brain activity may be moderated
by genetic factors underlying a familial history of AD. Lind
et al. [56] found that healthy middle aged and older adult
ε4 carriers displayed reduced neural activity in left inferior
parietal and anterior cingulate cortices than noncarriers
during a semantic categorization task. Borghesani et al. [24],
studying MTL activation in nondemented older adults with
a visuospatial memory task, also found that ε4 carriers
exhibited lower MTL activation during encoding. Filbey
et al. [12], while simultaneously ﬁnding regions more
activated in ε4 carriers (as discussed above), also found
that ε4 carriers exhibited less activity than noncarriers in
lateralfrontal,basalganglia, cingulate,parietal,andtemporal
regions during a working memory task. Reporting similar
ﬁndings, Xu et al. [25] found that middle aged ε4 carriers
showed reduced activation in left dorsal posterior cingulate,
precuneus, and anterior cingulate than noncarriers during
the recall portion of an episodic face recognition task. A
study by Suthana et al. [26] reported reduced hippocampal
activation in nondemented older ε4 carriers compared to
noncarriers during the encoding portion of a word memory
task.Theauthorsproposedthatthisdecreaseinhippocampal
activation may in fact allow for compensatory processes in
other regions, which would explain ﬁndings of decreased
activation in MTL regions in ε4carriers and may also explain
Kukolja et al.’s [4] ﬁnding of reduced memory retrieval with
increasing hippocampal activation among those with the ε4
allele.
While many of these studies support the compen-
satory recruitment aspect of our model [1]o fa n t a g o n i s t i c
pleiotropy and APOE, some studies did not ﬁnd evi-
dence of compensatory recruitment processes in ε4 carriers,
instead ﬁnding lower levels of activation in ε4 carriers than
noncarriers. A notable trend is that those studies ﬁnding
decreased levels of activity in ε4 carriers frequently did so in
regions commonly associated with AD (e.g., posterior cin-
gulate, precuneus, and hippocampus), while studies ﬁnding
increased activity in ε4 carriers commonly did so in regions
beyond those typically involved in early AD (e.g., prefrontal
cortex). As several authors have pointed out (e.g., [12]),
ε4 carriers may exhibit decrements in activity in regions
initially impacted in AD due to increased pathology burden
in these areas while continuing to compensate for these
decrements with increased activity in regions not initially
aﬀected by AD pathological processes. Another possible
explanation for discrepancies among studies could be due
to diﬀerences in vascular risk factors present in the samples.
Age-related vascular changes have been found to attenuate
neurovascular coupling upon which the BOLD response
in fMRI is based (e.g., [57, 58]). Such alterations can
complicate the interpretation of the BOLD response and
lead to erroneous conclusions if vascular changes are not
taken into account [57]. This is particularly relevant as the
APOE ε4 allele has been associated with vascular risk factors
(e.g., [59, 60]). Therefore, careful consideration of vascular
changes and clinically silent orprodromal forms ofdementia8 International Journal of Alzheimer’s Disease
are required to clarify the existence of compensatory neural
recruitment in older adult ε4 carriers.
5.APOEand Declining CognitioninOld Age
Much recent research has considered the implications of
APOE genotype for declining cognition in old age, and the
majority of this research has supported our proposal [1]
of exaggerated cognitive decline in ε4 carriers compared
t on o n c a r r i e r s .W h i l en o tu n i v e r s a l l yt h ec a s e[ 12, 21, 27],
most studies reporting cross-sectional diﬀerences by APOE
genotype found that ε4 carriers performed more poorly
in tasks of verbal and visual episodic memory [4, 28–35,
59]. Other reported discrepancies were in working memory
[30], general cognition [2, 4, 30, 36–38], category ﬂuency
[39], the Stroop task [40], matrix reasoning [14], and
symbol search [14]. Many studies also considered cognition
longitudinally and found ε4 carriers to display an increased
risk of developing mild cognitive impairment (MCI) (e.g.,
[41]), AD (e.g., [3]), or vascular dementia [59], although
other studies have failed to ﬁnd a relationship between the
ε4 allele and risk of developing MCI [42, 43]. Furthermore,
although less consistent in the literature, some reported
ﬁnding steeper rates of cognitive decline in ε4 carriers
compared to noncarriers [3, 31, 36, 37], with a number
reporting evidence of a dose-dependent response [3, 31, 59].
One interesting study by Casselli et al. [31] longitudinally
followed patients between 21 and 97 years of age. Growth
curve modeling predicted that APOE ε4 carriers begin to
declinein their memory around their 50’s, while participants
without an ε4 allele only begin to experience memory
decline in their 70’s. Memory decline also evidenced a dose-
dependent relationship, so that participants with two ε4
alleles were predicted to experience memory decline before
those with only one ε4 allele. Moreover, ε4 carriers had an
overall steeper rate of decline in memory, on the MMSE,
and on Judgment of Line Orientation than noncarriers.
Importantly, the study’s longitudinal design allowed authors
to remove from analysis those participants who eventually
developed MCI or dementia. The authors therefore suggest
that APOE detrimentally aﬀects cognition in older adults
independent of the inﬂuence of dementia. Liu et al. [48]
also examined the impact of the APOE ε4 allele on cognition
in a lifespan sample and reported that ε4 carriers’ cognitive
performance was only reduced compared to noncarriers in
those 50 and older; APOE ε4h a dn oe ﬀect on cognition in
younger age groups.
Carri´ on-Baralt et al. [44] reported intriguing results
with a sample of Puerto Rican oldest-old. They found ε4
carriers in this sample of nonagenarians to exhibit higher
performance than noncarriers in overall cognition as well
as measures of visuospatial abilities, naming, and attention.
The authors suggest that this unexpected ﬁnding may have
two sources. It may be that those who survive into their 90’s
have genetic protective factors that confer beneﬁt regardless
of APOE genotype. Because of the higher risk of dementia
and eventual mortality found with ε4 carriers, nonagenarian
ε4 carriers who survived beyond the prime ages for AD
development may be more likely to have this protective
factor and may therefore perform better than noncarriers.
A second possibility noted by Carri´ on-Baralt et al. [44]i s
thatAPOE mayexhibit antagonisticpleiotropiceﬀects,being
detrimental for cognition and survival in young-old age, but
being beneﬁcial in old-old age. Reporting similar ﬁndings,
Kozauer et al. [45] studied a large sample of two age cohorts
after a 22-year followup. Diﬀerences in cognition by APOE
status were only found in the younger cohort, which was in
their 50’s, in which ε4 carriers displayed worse performance
than noncarriers. These diﬀerences were not found at other
waves of data collection, implying that they developed upon
reaching middle and older ages. Interestingly, cognitive
diﬀerences by APOE status were not observed in the older
cohort, which had a mean age in the mid-70’s. This also
supports the contention that the APOE ε4 allele may not
be detrimental to those who survive into later ages without
developing dementia. Similarly, Welsh-Bohmer et al. [27],
who also studied APOE in oldest-old, found no relationship
between APOE and cognition. While these latter ﬁndings of
cognitive similarity by APOE status in the oldest-old may
not be as persuasive as those of Carri´ on-Baralt et al. [44],
they still suggest that the very common ﬁnding of cognitive
decline in older ε4 carriers may not hold true for the oldest-
old and may fail to do so because of antagonistic pleiotropy.
This argues for an extension of our model [1] into old-old
age, where APOE ε4 may again impart beneﬁcial cognitive
eﬀects to its carriers.
As suggested in our [1] model of APOE as an example
of antagonistic pleiotropy, much research has found that the
APOE ε4 allele is associated with disproportionate cognitive
d e c l i n ei no l da g e[ 3, 4, 14, 28–41, 59], although it may be
that the ε4 allele confers an advantage on its carriers who
reach old-old age without developing dementia, suggesting
an extension to our model [1, 27, 45, 48]. The association
of APOE ε4 with cognitive decline follows from ﬁndings
suggesting a close relationship of the ε4 allele with amyloid
neuropathology, a hallmark of AD [61–65]. Indeed, many
individual studies and reviews have reported APOE to be
stronglyassociatedwithAβ42,themostinsolubleformofthe
Aβ peptide, which aggregates to form senile plaques in AD
(e.g., [61, 64, 65]). Some studies have also demonstrated a
dose-dependentrelationship betweentheAPOE ε4a l l e l ea n d
amyloid pathology, in which ε4 homozygotes exhibit more
amyloid pathology than those with only one ε4 allele (e.g.,
[64, 65]). However, the demonstrated relationship between
the APOE ε4 allele and AD-related amyloid pathology might
argue against the ability of APOE to confer protective eﬀects
to its old-old nondemented carriers. With respect to this
possibility, it is important to note that studies have found
that amyloid pathology, while being strongly associated with
the development of AD, does not account for all of the
cognitive decline found in these patients (e.g., [61, 65,
66]). Other biomarkers, particularly brain atrophy and tau
pathology, commonly account fora large portion ofvariance
in cognitive decline found in AD (e.g., [61, 65, 66]). The fact
that the APOE ε4 allele has not been as strongly associated
withtheseotherADbiomarkers[61,65,66]m a ye xpla inw h y
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despite the strong association of the ε4 allele with amyloid
pathology.
6.Conclusionsand Recommendations
Our model [1] of antagonistic pleiotropy in APOE was
critically re-evaluated in light of recent research. Some
aspects of the model were strongly supported. Research
suggests that younger ε4 carriers do indeed exhibit com-
pensatory neural recruitment, as proposed by our model
[1]. However, our prediction of a predilection for right
hemisphere frontal regions in this compensatory process
was not clearly corroborated. It instead seems that young
ε4 carriers invoke compensatory processes in task-related
regions. The cognitive decline in older ε4 carriers predicted
by the model was also supported in recent literature,
revealing a strong eﬀectonmemory aswell asothercognitive
domains. Yet inconsistent evidence was found to support
other aspects of the model. For instance, the presence of
compensatory neural recruitment in older ε4 carriers was
not unanimously supported. Studies with older ε4 carriers
also only partially supported our prediction [1]o fah i g h e r
likelihoodofrecruitmentofrightfrontal regions. Diﬀerences
in compensatory regions may be linked to type of task, as
those thought to invokemore of a right hemisphere response
also found evidencefor right hemisphere compensatory pro-
cesses, while left hemisphere compensatory processes were
occasionally observed for tasks emphasizing language that
would be thought to rely more heavily on left hemisphere
regions. It is also unclear whether young ε4 carriers show
better cognitive performance than noncarriers. As discussed,
these inconsistent ﬁndings may be explained by the need to
consider APOE and cognition in narrow age ranges or to sta-
tisticallytesttheinteractionbetweenAPOEgenotypeandage
in predicting cognition for lifespan samples. It also appears
important to control for detrimental health comorbidities
t h a tm a yb em o r ep r e v a l e n ti nε4 carriers in such analyses.
However, if it is determined that APOE ε4 carriers do not
show a cognitive beneﬁt in early life, this strongly argues
against APOE as displaying antagonistic pleiotropic eﬀects.
In fact, ﬁndings of compensatory recruitment in young ε4
carriers in the presence of similar, instead of enhanced,
cognitive performance implies that the ε4 allele may be
detrimental even in young ages, as young carriers have to
activate more brain regions to produce the same level of
performance as noncarriers. Research in this area is vital
to further evaluate the antagonistic pleiotropy hypothesis of
APOE.
In light of the reviewed research, we suggest certain
revisions to our model [1] of antagonistic pleiotropy and
APOE. In the absence of conclusive contrary ﬁndings, we
maintain that APOE ε4 carriers exhibit cognitive beneﬁts
early in life. We also propose that compensatory neural
recruitment processes occur in task-related regions in young
ε4carriers buttransfer tofrontal regions among olderadults,
once task-related regions become overburdened with AD
pathology. While compensatory regions may be in the right
hemisphere, lateralization of the compensatory response
does not seem to be a consistent trend. Second, we propose
that cognitive decline will begin much earlier in ε4 carriers
and will progress more rapidly. In light of new research
[27, 44, 45] ,w ea l s op r e d i c tt h a tt h eA P O Eε4a l l e l ea g a i n
becomes beneﬁcial in the oldest-old, who survive into old-
old age without developing dementia. Additional research is
needed to test this notion, as functional imaging to examine
compensatory recruitment in nonagenarian populations of
ε4 carriers would be particularly elucidating.
The ﬁnding of cognitive superiority in nondemented ε4
nonagenarians suggests a second hypothesis of gene-gene
interaction thatmay explaintheapparentAPOEantagonistic
pleiotropic eﬀects as well as the inconsistencies in the litera-
ture. It may be that the APOE ε4 allele is not antagonistically
pleiotropic but instead interacts with other AD risk factors
to diﬀerentially inﬂuence cognition depending on a person’s
proﬁleofrisk.Indeed,APOEhasbeenfoundbymany studies
to interact with a family history of AD to inﬂuence cognition
(e.g., [25, 29]) and also to interact with other risk genes such
as APOCI AA, BCHE, and CHRNA4 [59, 67, 68]. Therefore,
it may be that among people without AD risk factors, APOE
ε4 does not adversely aﬀect cognition and could perhaps
be beneﬁcial to its carriers. Some have gone so far as to
suggest that APOE has no inﬂuence on cognition beyond
increasing risk for AD [69]. These authors suggest that
APOE, while putting one at risk for prodromal dementia,
does not create a speciﬁc cognitive phenotype of its own
[69]. APOE’s interaction with other genetic risk factors to
inﬂuence cognition would explain why only some young ε4
carriers showenhanced cognitionovernoncarriers, why only
some ε4 carriers show disproportionate cognitive declines
with age, and why nondemented oldest-old ε4 carriers
show cognitive enhancements. Perhaps those children with
APOE ε4 and other AD risk factors are those that show no
diﬀerence from noncarriers, due to compensatory recruit-
ment processes, or actually show reductions in cognitive
abilities compared to noncarriers. Perhaps those children
with APOE ε4 and other AD risk factors are the ones to show
disproportionate cognitive decline in old age compared to
noncarriers, whereas ε4 carriers without other risk factors
do not show more cognitive decline than would be expected.
This hypothesis of the interaction of APOE with AD-speciﬁc
risk factors is further supported by the lack of associations
between APOE and cognition in other diseases such as
multiple sclerosis [70]. Future research in genetics and
epigenetics is needed which carefully considers participants’
AD risk proﬁles. Careful, comprehensive studies conducted
in this way will help the ﬁeld determine whether APOE
displays antagonistic pleiotropy or gene-gene interactions
with other AD risk factors.
This paper suggests several avenues for future research as
well as other important factors when considering APOE as
an example of antagonistic pleiotropy. Beyond considering
neurovascular decoupling with age and participants’ AD risk
proﬁles, future research examining the impact of APOE ε4
allele on cognition and neural activity across the lifespan is
needed. Continued evaluation of the antagonistic pleiotropy
andgene-geneinteractionhypotheses ofAPOEwill movethe
ﬁeld closer to realizing eﬀective treatments and preventative
measures for AD.10 International Journal of Alzheimer’s Disease
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